In Case You Haven’t Noticed: SunTrust Banks, Inc. (STI), Sorrento Therapeutics, Inc. (SRNE)

A look at its monthly performance shows that SunTrust Banks, Inc. (NYSE:STI) has recorded a -2.24% fall over the past 30 days. Over the past 12 months the stock has embarked on a drop that has seen it decline -11.32% and is now up by 27.06% since start of this year. The equity price rose 1.14% this week, a trend that has led to both investors and traders taking note of the stock. Its equity price climbed by 17.57% over the past three months which led to its overall six-month decrease to stand at -13.64%.

The shares of SunTrust Banks, Inc. (STI) dropped by -14.64% or -$10.99 from its last recorded high of $75.08 which it attained on August 21 to close at $64.09 per share. Over the past 52 weeks, the shares of SunTrust Banks, Inc. has been trading as low as $46.05 before witnessing a massive surge by 39.17% or $18.04. This price movement has led to the STI stock receiving more attention and has become one to watch out for. It jumped by 0.14% on Thursday and this got the market excited. The stock’s beta now stands at 1.55 and when compared to its 200-day moving average and its 50-day moving average, STI price stands -1.26% below and 4.81% above respectively. Its average daily volatility for this week is 1.47% which is less than the 1.72% recorded over the past month.

Experts from research firms are bullish about the near-term performance of SunTrust Banks, Inc. with most of them predicting a $71.2 price target on a short-term (12 months) basis. The average price target by the analysts will see a 11.09% rise in the stock and would lead to STI’s market cap to surge to $31.5B. The stock has been rated an average 2.5, which roughly stands towards the bearish end of the spectrum. Reuters looked into the 25 analysts that track SunTrust Banks, Inc. (NYSE:STI) and find out that 17 of them rated it as a Hold. 8 of the 8 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

A look at STI technical analysis shows that its 14-day Relative Strength Index (RSI) is in a neutral zone after reaching 53.6 point. Its trading volume has lost -3301069 shares compared to readings over the past three months as it recently exchanged 1938931 shares. This means there is reduced activity from short-term traders as per session, its average trading volume is 5240000 shares, and this is 0.37 times the normal volume.

The price of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) currently stands at $2.43 after it went down by $-0.01 or -0.41% and has found a strong support at $2.33 a share. If the SRNE price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $2.24 mark would also be bad for the stock as it means that the stock would plunge by 7.82% from its current position. However, if the stock price is able to trade above the resistance point around $2.48, then it could likely surge higher to try and break the upward resistance which stands at $2.54 a share. Its average daily volatility over the past one month stands at 6.93%. The stock has plunged by 5.76% from its 52-weeks high of $2.29 which it reached on Mar. 21, 2018. In general, it is 25.93% above its 52-weeks lowest point which stands at $1.8 and this setback was observed on Aug. 03, 2019.

Analysts have predicted a price target for Sorrento Therapeutics, Inc. (SRNE) for 1 year and it stands at an average $20.17/share. This means that it would likely increase by 730.04% from its current position. The current price of the stock has been moving between $2.29 and $2.44. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $10. On the other hand, one analyst is super bullish about the price, setting a target as high as $40.

The SRNE stock Stochastic Oscillator (%D) is at 75.13%, which means that it is currently neutral. The shares P/S ratio stands at 8.08 which compares to the 49.52 recorded by the industry or the 8.39 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 17.9% over the past five years.

Analysts view Sorrento Therapeutics, Inc. (NASDAQ:SRNE) as a Buy, with 0 consensus rating. Reuters surveyed 3 analysts that follow SRNE and found that 0 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 3 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying Sorrento Therapeutics, Inc. (SRNE) shares or sell it if they already own it.